Hildur Helgadóttir

2.6k total citations
64 papers, 1.3k citations indexed

About

Hildur Helgadóttir is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Hildur Helgadóttir has authored 64 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 23 papers in Molecular Biology and 22 papers in Immunology. Recurrent topics in Hildur Helgadóttir's work include Cutaneous Melanoma Detection and Management (26 papers), Immunotherapy and Immune Responses (22 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Hildur Helgadóttir is often cited by papers focused on Cutaneous Melanoma Detection and Management (26 papers), Immunotherapy and Immune Responses (22 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Hildur Helgadóttir collaborates with scholars based in Sweden, Italy and Spain. Hildur Helgadóttir's co-authors include Veronica Höiom, Håkan Olsson, Rainer Tuominen, Johan Hansson, Christos Gekas, Hanna Mikkola, Stuart H. Orkin, Göran Jönsson, Thorsten M. Schlaeger and Stefan Karlsson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Hildur Helgadóttir

52 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hildur Helgadóttir Sweden	19	593	537	332	230	184	64	1.3k
Marjo Hahka‐Kemppinen Finland	18	545 0.9×	651 1.2×	220 0.7×	275 1.2×	198 1.1×	33	1.1k
Audrey Rapinat France	13	425 0.7×	312 0.6×	180 0.5×	170 0.7×	190 1.0×	17	896
Charles Decraene France	22	645 1.1×	596 1.1×	140 0.4×	78 0.3×	571 3.1×	40	1.4k
Emanuele Palescandolo United States	15	830 1.4×	472 0.9×	106 0.3×	44 0.2×	315 1.7×	19	1.6k
Ana Carneiro Sweden	16	467 0.8×	650 1.2×	272 0.8×	110 0.5×	145 0.8×	46	1.1k
Riccardo Danielli Italy	22	728 1.2×	1.4k 2.6×	1.0k 3.1×	168 0.7×	133 0.7×	45	2.4k
Allan Topham United States	17	700 1.2×	1.2k 2.2×	342 1.0×	1.3k 5.9×	391 2.1×	24	2.6k
Gloria Meng United States	18	1.2k 2.0×	565 1.1×	456 1.4×	29 0.1×	246 1.3×	21	2.3k
Kristian W. Pajtler Germany	24	1.2k 2.0×	284 0.5×	99 0.3×	29 0.1×	371 2.0×	91	2.2k
Matthew J. Rioth United States	12	347 0.6×	282 0.5×	146 0.4×	41 0.2×	146 0.8×	28	717

Countries citing papers authored by Hildur Helgadóttir

Since Specialization

Citations

This map shows the geographic impact of Hildur Helgadóttir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hildur Helgadóttir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hildur Helgadóttir more than expected).

Fields of papers citing papers by Hildur Helgadóttir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hildur Helgadóttir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hildur Helgadóttir. The network helps show where Hildur Helgadóttir may publish in the future.

Co-authorship network of co-authors of Hildur Helgadóttir

This figure shows the co-authorship network connecting the top 25 collaborators of Hildur Helgadóttir. A scholar is included among the top collaborators of Hildur Helgadóttir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hildur Helgadóttir. Hildur Helgadóttir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huibers, Anne, Christian U. Blank, Gustav Ullenhag, et al.. (2025). Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma – A Swedish retrospective real-world study (NEO-MEL). European Journal of Cancer. 224. 115485–115485.

Donia, Marco, Henrik Jespersen, Mathilde Jalving, et al.. (2025). Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028. ESMO Open. 10(3). 104295–104295. 2 indexed citations

Portelli, Francesca, et al.. (2025). Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trends. Journal of the European Academy of Dermatology and Venereology. 40(1). 90–98. 2 indexed citations

All‐Eriksson, Charlotta, Christian Cahlin, Nils Elander, et al.. (2024). Long-term overall survival after isolated liver perfusion with melphalan in patients with isolated liver metastases of uveal melanoma (SCANDIUM trial).. Journal of Clinical Oncology. 42(16_suppl). 9532–9532.

Hoyt, David, Gregory J. Stoddard, Ashley Snyder, et al.. (2024). Declining invasive and rising in situ melanoma incidence trends in Iceland: A nationwide cohort study. Journal of the European Academy of Dermatology and Venereology. 39(7). 1278–1284.

Helgadóttir, Hildur, K. Nielsen, Francesca Portelli, et al.. (2024). Melanoma Incidence and Mortality Trends Among Patients Aged 59 Years or Younger in Sweden. JAMA Dermatology. 160(11). 1201–1201. 6 indexed citations

Helgadóttir, Hildur, et al.. (2023). Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study. JNCI Journal of the National Cancer Institute. 115(9). 1077–1084. 15 indexed citations

Bagge, Roger Olofsson, Charlotta All‐Eriksson, Christian Cahlin, et al.. (2023). Survival after isolated hepatic perfusion as a treatment for uveal melanoma liver metastases: Results from a randomized controlled trial (the SCANDIUM trial).. Journal of Clinical Oncology. 41(17_suppl). LBA9512–LBA9512. 1 indexed citations

Bagge, Roger Olofsson, Charlotta All‐Eriksson, Christian Cahlin, et al.. (2023). Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). Journal of Clinical Oncology. 41(16). 3042–3050. 33 indexed citations

10.

Helgadóttir, Hildur, et al.. (2023). Familial features affecting the melanoma risk in CDKN2A -negative melanoma families: a study based on the Swedish Cancer Registry. Acta Oncologica. 62(12). 1967–1972.

11.

Silander, Gustav, Åke Borg, Jenny Pettersson, et al.. (2021). CDKN2A genetic testing in melanoma-prone families in Sweden in the years 2015–2020: implications for novel national recommendations. Acta Oncologica. 60(7). 888–896. 9 indexed citations

12.

Ascierto, P.A., Mario Mandalà, Pier Francesco Ferrucci, et al.. (2021). LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study. Annals of Oncology. 32. S1316–S1317. 18 indexed citations

13.

Helgadóttir, Hildur, Yvonne Brandberg, Johan Hansson, et al.. (2020). TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma. BMC Cancer. 20(1). 1197–1197. 8 indexed citations

14.

Helgadóttir, Hildur, Karolin Isaksson, Christian Ingvar, et al.. (2020). Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study. JNCI Journal of the National Cancer Institute. 113(3). 318–328. 19 indexed citations

15.

Ascierto, Paolo A., Mario Mandalà, Pier Francesco Ferrucci, et al.. (2020). LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study). Annals of Oncology. 31. S1173–S1174. 19 indexed citations

16.

Jespersen, Henrik, Roger Olofsson Bagge, Gustav Ullenhag, et al.. (2019). Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. BMC Cancer. 19(1). 415–415. 52 indexed citations

17.

Helgadóttir, Hildur, Håkan Olsson, Margaret A. Tucker, et al.. (2017). Phenocopies in melanoma-prone families with germ-line CDKN2A mutations. Genetics in Medicine. 20(9). 1087–1090. 8 indexed citations

18.

Helgadóttir, Hildur, Veronica Höiom, Rainer Tuominen, et al.. (2016). GermlineCDKN2AMutation Status and Survival in Familial Melanoma Cases. JNCI Journal of the National Cancer Institute. 108(11). djw135–djw135. 47 indexed citations

19.

Schlaeger, Thorsten M., Hanna Mikkola, Christos Gekas, Hildur Helgadóttir, & Stuart H. Orkin. (2005). Tie2Cre-mediated gene ablation defines the stem-cell leukemia gene (SCL/tal1)–dependent window during hematopoietic stem-cell development. Blood. 105(10). 3871–3874. 92 indexed citations

20.

Jónsson, Pálmi V., et al.. (1997). Siðfræðilegir þættir við takmörkun meðferðar við lok lífs. Læknablaðið. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact